Traves D Crabtree1, Varun Puri2, Clifford Robinson3, Jeffrey Bradley3, Stephen Broderick2, G Alexander Patterson2, Jingxia Liu4, Joanne F Musick2, Jennifer M Bell2, Michael Yang2, Bryan F Meyers2. 1. Division of Cardiothoracic Surgery, Department of Surgery, Washington University School of Medicine, St Louis, Mo. Electronic address: crabtreet@wudosis.wustl.edu. 2. Division of Cardiothoracic Surgery, Department of Surgery, Washington University School of Medicine, St Louis, Mo. 3. Department of Radiation Oncology, Washington University School of Medicine, St Louis, Mo. 4. Division of Biostatistics, Washington University School of Medicine, St Louis, Mo.
Abstract
OBJECTIVES: Comparative studies of survival between stereotactic body radiation therapy (SBRT) and surgery have been limited by lack of comparisons of recurrence patterns between matched cohorts in non-small cell lung cancer (NSCLC). METHODS: All patients undergoing treatment with surgery or SBRT for clinical stage I NSCLC between June 2004 and December 2010 were reviewed. Age, tumor characteristics, comorbidity score, pulmonary function, overall survival (OS), disease-free survival (DFS), and recurrence data were collected and propensity matching performed. RESULTS: The mean age for surgery (n = 458) was 65.8 ± 10.5 versus 74.4 ± 9.4 for SBRT (n = 151) (P < .0001). For the entire surgical cohort, 3-year OS was 78% and DFS was 72%. For the entire SBRT cohort, 3-year OS was 47% and DFS was 42%. The overall local recurrence rate for surgery was 2.6%. The overall local recurrence rate for SBRT was 10.7%. A propensity-matched comparison based on age, tumor size, Adult Comorbidity Evaluation comorbidity score, forced expiratory volume in the first second of expiration, and tumor location resulted in 56 matched pairs. The 3-year OS was 52% versus 68% for SBRT and surgery (P = .05); DFS was 47% versus 65% (P = .01). At 3 years, local recurrence-free survival was 90% versus 92% for SBRT and surgery (P = .07). CONCLUSIONS: Although surgical resection seems to result in better OS and DFS versus SBRT, matching these disparate cohorts of patients remains challenging. Participation in clinical trials is essential to define the indications and relative efficacy of surgery and radiation therapy in a high-risk population with stage I NSCLC.
OBJECTIVES: Comparative studies of survival between stereotactic body radiation therapy (SBRT) and surgery have been limited by lack of comparisons of recurrence patterns between matched cohorts in non-small cell lung cancer (NSCLC). METHODS: All patients undergoing treatment with surgery or SBRT for clinical stage I NSCLC between June 2004 and December 2010 were reviewed. Age, tumor characteristics, comorbidity score, pulmonary function, overall survival (OS), disease-free survival (DFS), and recurrence data were collected and propensity matching performed. RESULTS: The mean age for surgery (n = 458) was 65.8 ± 10.5 versus 74.4 ± 9.4 for SBRT (n = 151) (P < .0001). For the entire surgical cohort, 3-year OS was 78% and DFS was 72%. For the entire SBRT cohort, 3-year OS was 47% and DFS was 42%. The overall local recurrence rate for surgery was 2.6%. The overall local recurrence rate for SBRT was 10.7%. A propensity-matched comparison based on age, tumor size, Adult Comorbidity Evaluation comorbidity score, forced expiratory volume in the first second of expiration, and tumor location resulted in 56 matched pairs. The 3-year OS was 52% versus 68% for SBRT and surgery (P = .05); DFS was 47% versus 65% (P = .01). At 3 years, local recurrence-free survival was 90% versus 92% for SBRT and surgery (P = .07). CONCLUSIONS: Although surgical resection seems to result in better OS and DFS versus SBRT, matching these disparate cohorts of patients remains challenging. Participation in clinical trials is essential to define the indications and relative efficacy of surgery and radiation therapy in a high-risk population with stage I NSCLC.
Authors: Cliff G Robinson; Todd A DeWees; Issam M El Naqa; Kimberly M Creach; Jeffrey R Olsen; Traves D Crabtree; Bryan F Meyers; Varun Puri; Jennifer M Bell; Parag J Parikh; Jeffrey D Bradley Journal: J Thorac Oncol Date: 2013-02 Impact factor: 15.609
Authors: Cameron D Wright; Henning A Gaissert; Joshua D Grab; Sean M O'Brien; Eric D Peterson; Mark S Allen Journal: Ann Thorac Surg Date: 2008-06 Impact factor: 4.330
Authors: N Martini; M S Bains; M E Burt; M F Zakowski; P McCormack; V W Rusch; R J Ginsberg Journal: J Thorac Cardiovasc Surg Date: 1995-01 Impact factor: 5.209
Authors: Jeffrey D Bradley; Issam El Naqa; Robert E Drzymala; Marco Trovo; Griffin Jones; Mary Dee Denning Journal: Int J Radiat Oncol Biol Phys Date: 2009-09-30 Impact factor: 7.038
Authors: Christopher Cao; Daniel Wang; Caroline Chung; David Tian; Andreas Rimner; James Huang; David R Jones Journal: J Thorac Cardiovasc Surg Date: 2018-09-15 Impact factor: 5.209
Authors: Varun Puri; Traves D Crabtree; Jennifer M Bell; Stephen R Broderick; Daniel Morgensztern; Graham A Colditz; Daniel Kreisel; A Sasha Krupnick; G Alexander Patterson; Bryan F Meyers; Aalok Patel; Clifford G Robinson Journal: J Thorac Oncol Date: 2015-12 Impact factor: 15.609
Authors: Cheng S Jin; Hironobu Wada; Takashi Anayama; Patrick Z McVeigh; Hsin Pei Hu; Kentaro Hirohashi; Takahiro Nakajima; Tatsuya Kato; Shaf Keshavjee; David Hwang; Brian C Wilson; Gang Zheng; Kazuhiro Yasufuku Journal: Cancer Res Date: 2016-08-19 Impact factor: 12.701